Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Goldman Sachs

She almost quit Goldman when she didn't make partner

Goldman's global head of corporate engagement and president of the Goldman Sachs Foundation will now have oversight of the $3 billion Urban Investment Group.

Fortune

A Closer Look at 16 Analyst Recommendations For Charles Schwab

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Charles Schwab (NYSE:SCHW) in the last three months.

Benzinga

Benzinga Bulls And Bears: Tesla, GameStop, Nvidia, Bitcoin, And Dogecoin Analyst Flags $1.30-$1.50 As Key Target

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

NIO Stock Price 2025 Prediction: Will NIO Fall Even Further Next Year?

NIO stock is set to fall for a fourth consecutive year and trades at a fraction of its 2021 highs. Can the Chinese EV company make a comeback in 2025?

Barchart

Stocks Finish Mostly Higher on Positive US Economic News

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.28%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.92%. Stocks on Friday settled mixed, with the S&P 500 and Nasdaq 100 posting new...

Barchart

Lululemon's Strong Earnings and Share Buyback Push Analysts to Increase Price Forecast

Analysts raise Lululemon's price targets, citing strong Q3 results, international growth, product innovation, and future expansion opportunities.

Benzinga

Commercial Real Estate Recovery: Goldman Sachs Names 3 Top Stocks For 2025

Goldman Sachs bullish on CRE services stocks: CBRE, NMRK, JLL top picks for 2025. Recovery in 2024 was driven by stabilizing property values and financing conditions.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Expert Outlook: Wells Fargo Through The Eyes Of 14 Analysts

Throughout the last three months, 14 analysts have evaluated Wells Fargo (NYSE:WFC), offering a diverse set of opinions from bullish to bearish.

Benzinga

A Glimpse Into The Expert Outlook On Robinhood Markets Through 28 Analysts

Robinhood Markets (NASDAQ:HOOD) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Benzinga

S&P 500 and Nasdaq 100 Post New Record Highs on Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) today is up +0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.67%. Stocks are climbing today, with the S&P 500 and Nasdaq 100 posting new record...

Barchart

How Is Goldman Sachs' Stock Performance Compared to Other Capital Markets Stocks?

Goldman Sachs has outperformed its industry peers over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Evaluating Payoneer Global: Insights From 9 Financial Analysts

Payoneer Global (NASDAQ:PAYO) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Navigating 15 Analyst Ratings For Duolingo

Throughout the last three months, 15 analysts have evaluated Duolingo (NASDAQ:DUOL), offering a diverse set of opinions from bullish to bearish.

Benzinga

4 Analysts Have This To Say About Maravai LifeSciences

Throughout the last three months, 4 analysts have evaluated Maravai LifeSciences (NASDAQ:MRVI), offering a diverse set of opinions from bullish to bearish.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Assessing DoubleVerify Hldgs: Insights From 20 Financial Analysts

In the last three months, 20 analysts have published ratings on DoubleVerify Hldgs (NYSE:DV), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Navigating 9 Analyst Ratings For Veracyte

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

Applovin Set To Capitalize On AI Frenzy, Ad Growth, Analyst Cautions On Near-Term Volatility

Goldman Sachs analyst maintains Neutral rating on Applovin Corp (NASDAQ: APP) with $220 price target.

Benzinga

Marvell Technology Posts Solid Q3 Beat: Analysts Raise Forecasts, Expect 40%-50% Earnings Growth

Marvell Technology reported upbeat earnings amid exciting earnings season. Analysts raised their price targets, expecting strong growth.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Breaking Down M&T Bank: 15 Analysts Share Their Views

During the last three months, 15 analysts shared their evaluations of MT Bank (NYSE:MTB), revealing diverse outlooks from bullish to bearish.

Barchart

3 Energy ETFs to Invest in the Data Center Power Surge

The growing demand for power from data centers is creating an investment opportunity in the energy sector, and three ETFs - UNG, FCG, and GPOW - offer distinct approaches to tap into the natural gas surge and capitalize on this trend.

Fortune

BlackRock’s $12 billion purchase of HPS gives firm a bigger chunk of red-hot private credit market

BlackRock inks third big deal this year after scooping up GIP for $12.5 billion and Preqin for $3.2 bln.

Benzinga

17 Analysts Assess Regions Finl: What You Need To Know

17 analysts have shared their evaluations of Regions Finl (NYSE:RF) during the recent three months, expressing a mix of bullish and bearish perspectives.

The Independent UK

Wall Street doesn’t buy Trump vows on immigration, cost cuts

Investors also have doubts that Elon Musk will severely cut government spending

Benzinga

Trump Told Trudeau Canada Could Dodge Tariffs As 51st State: Which Sectors Could Be Hit

Donald Trump's plan for 25% tariffs could put Canada stocks and ETFs under pressure.

Benzinga

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

1 … 40 41 42 43

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.